Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 313-320

  Wallis, Carole L ^a   Papathanasopolous, Maria A ^a   Fox, Matthew ^a,b,c   Conradie, Francesca ^a   Ive, Prudence ^a   Orrell, Catherine ^d   Zeinecker, Jennifer ^d   Sanne, Ian ^a   Wood, Robin ^d   McIntyre, James ^e   Stevens, Wendy ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e ANOVA HEALTH INSTITUTE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; SOUTH AFRICA; STRUCTURAL GENE; TREATMENT DURATION; VIRUS CLASSIFICATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SOUTH AFRICA; STAVUDINE; VIRAL LOAD;

EID: 84860345319     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1985     Document Type: Article

References (24)

1. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
2. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Secondline treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-518.
3. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597. (Pubitemid 351706742)
4. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
5. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-484.
6. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
7. Doualla-Bell F, Gaolathe T, Avalos A, et al. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. J Int AIDS Soc 2009; 12:25.
8. Lyagoba F, Dunn DT, Pillay D, et al. Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr 2010; 55:277-283.
9. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185. (Pubitemid 44865165)
10. Coutsinos D, Invernizzi C F, Xu H, Brenner BG, Wainberg MA. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 2010; 20:117-131.
11. Coutsinos D, Invernizzi C F, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009; 83:2029-2033.
12. Delaugerre C, Flandre P, Chaix ML, et al. Protease inhibitor resistance analysis in the MONARK trial comparing firstline lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
13. Department of Health. National antiretroviral treatment guidelines. (Updated 2004. Accessed 29 October 2010) Available from http://southafrica. usembassy.gov/media/2004-doh-art-guidelines.pdf.
14. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376:33-40.
15. Wallis CL, Papathanasopoulos MA, Lakhi S, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010; 163:505-508.
16. Los Alamos National Laboratory. Los Alamos HIV databases. (Accessed 1 November 2011). Available from http://www.hiv.lanl.gov/
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-68.
18. Alcantara LC, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2009; 37:W634-W642.
19. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800. (Pubitemid 41535530)
20. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43:1329-1336. (Pubitemid 44706463)
21. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732. (Pubitemid 46568629)
22. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006; 7:442-450. (Pubitemid 44269811)
23. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13. (Pubitemid 44030369)
24. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Chantratitra W. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting. AIDS Patient Care STDS 2007; 21:711-714. (Pubitemid 47614388)